恒瑞医药心肌肌球蛋白抑制剂HRS-1893达成海外授权

Core Viewpoint - HengRui Medicine has entered into an exclusive licensing agreement with Braveheart Bio for the development of the Myosin small molecule inhibitor HRS-1893, indicating a strategic move to enhance its product pipeline and potential revenue streams [1] Financial Summary - Braveheart Bio will pay HengRui Medicine a total of $75 million, which includes an upfront payment of $65 million (comprising $32.5 million in cash and $32.5 million in equity) and a $10 million milestone payment upon completion of technology transfer [1] - HengRui Medicine is eligible to receive additional milestone payments related to clinical development and sales, potentially amounting to $1.013 billion [1]